SCHEMBL13645807

SCHEMBL13645807

CC(=O)NCC(=O)NCC1CCCO1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
HPGD P15428 6/20 0.62
TP53 P04637 1/20 0.62
ALOX12 P18054 1/20 0.62
KDM4E B2RXH2 2/20 0.56
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
HTT P42858 1/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
PKM P14618 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409226 0.88 SMN1; SMN2 (0.64) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL12409354 0.88 SMN1; SMN2 (0.64) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL1101625 0.88 SMN1; SMN2 (0.64) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL24323573 0.85 SMN1; SMN2 (0.66) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL13645848 0.84 USP2 (0.69) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL15492723 0.83 SMN1; SMN2 (0.57) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL24324224 0.83 USP2 (0.62) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL3154658 0.81 USP2 (0.70) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL26789169 0.81 USP2 (0.70) USP2SMN1; SMN2HPGDTP53ALOX12
SCHEMBL26789172 0.81 USP2 (0.70) USP2SMN1; SMN2HPGDTP53ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof HLA-C, TPMT, TAP1 USP2 3325/4885SMN1; SMN2 3178/4885HPGD 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.